Sex Differences in Atrial Fibrillation and Its Complications

Current Cardiovascular Risk Reports

Volumn 4, Issue 3, 2010, Pages 237-243

  Conen, David ^a,b   Albert, Christine M ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atrial fibrillation; Cardiovascular disease; Gender; Review; Risk factors

Indexed keywords

EID: 80052868862     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-010-0089-5     Document Type: Review

References (73)

1. Conen D, Osswald S, Albert CM: Epidemiology of atrial fibrillation. Swiss Med Wkly 2009, 139: 346-352.
2. Feinberg WM, Blackshear JL, Laupacis A, et al.: Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995, 155: 469-473.
3. Miyasaka Y, Barnes ME, Gersh BJ, et al.: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980-2000, and implications on the projections for future prevalence. Circulation 2006, 114: 119-125. (Published erratum appears in Circulation 2006, 114: e498.).
4. Benjamin EJ, Levy D, Vaziri SM, et al.: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271: 840-844.
5. Go AS, Hylek EM, Phillips KA, et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285: 2370-2375.
6. Fang MC, Singer DE, Chang Y, et al.: Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005, 112: 1687-1691.
7. Lloyd-Jones DM, Wang TJ, Leip EP, et al.: Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110: 1042-1046.
8. Cha YM, Redfield MM, Shen WK, Gersh BJ: Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 2004, 109: 2839-2843.
9. Wang TJ, Larson MG, Levy D, et al.: Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003, 107: 2920-2925.
10. Ehrlich JR, Nattel S, Hohnloser SH: Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002, 13: 399-405.
11. Psaty BM, Manolio TA, Kuller LH, et al.: Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997, 96: 2455-2461.
12. Dagres N, Nieuwlaat R, Vardas PE, et al.: Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 2007, 49: 572-577.
13. Humphries KH, Kerr CR, Connolly SJ, et al.: New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 2001, 103: 2365-2370.
14. Krahn AD, Manfreda J, Tate RB, et al.: The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995, 98: 476-484.
15. • Mitchell GF, Vasan RS, Keyes MJ, et al.: Pulse pressure and risk of new-onset atrial fibrillation. JAMA 2007, 297: 709-715. This is the first report on the potential importance of pulse pressure in the pathogenesis of AF.
16. • Conen D, Tedrow UB, Koplan BA, et al.: Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women. Circulation 2009, 119: 2146-2152. This is the first report to show that nonhypertensive blood pressure values are associated with new-onset AF in women.
17. Dublin S, French B, Glazer NL, et al.: Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006, 166: 2322-2328.
18. Frost L, Hune LJ, Vestergaard P: Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 2005, 118: 489-495.
19. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004, 292: 2471-2477.
20. Tedrow UB, Conen D, Ridker PM, et al.: The long and short term impact of elevated body mass index on risk of new atrial fibrillation in the Women's Health Study. J Am Coll Cardiol 2010 (in press).
21. Paeratakul S, Lovejoy JC, Ryan DH, Bray GA: The relation of gender, race and socioeconomic status to obesity and obesity comorbidities in a sample of US adults. Int J Obes Relat Metab Disord 2002, 26: 1205-1210.
22. Tsang TS, Barnes ME, Miyasaka Y, et al.: Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 2008, 29: 2227-2233.
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-2497.
24. Watanabe H, Tanabe N, Watanabe T, et al.: Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008, 117: 1255-1260.
25. Lee IM, Rexrode KM, Cook NR, et al.: Physical activity and coronary heart disease in women: is "no pain, no gain" passe? JAMA 2001, 285: 1447-1454.
26. Karjalainen J, Kujala UM, Kaprio J, et al.: Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ 1998, 316: 1784-1785.
27. Mont L, Sambola A, Brugada J, et al.: Long-lasting sport practice and lone atrial fibrillation. Eur Heart J 2002, 23: 477-482.
28. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D: Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation 2008, 118: 800-807.
29. Aizer A, Gaziano JM, Cook NR, et al.: Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009, 103: 1572-1577.
30. Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350: 1387-1397.
31. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336: 973-979. (Published erratum appears in N Engl J Med 1997, 337: 356.).
32. Lo B, Fijnheer R, Nierich AP, et al.: C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann Thorac Surg 2005, 79: 1530-1535.
33. Frustaci A, Chimenti C, Bellocci F, et al.: Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997, 96: 1180-1184.
34. Nakamura Y, Nakamura K, Fukushima-Kusano K, et al.: Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res 2003, 111: 137-142.
35. Aviles RJ, Martin DO, Apperson-Hansen C, et al.: Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108: 3006-3010.
36. Dernellis J, Panaretou M: Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am J Cardiol 2006, 97: 245-248.
37. • Schnabel RB, Larson MG, Yamamoto JF, et al.: Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010, 121: 200-207. This article confirms a significant association between high-sensitivity CRP and AF.
38. Conen D, Ridker PM, Everett BM, et al.: Inflammation and Risk of Incident Atrial Fibrillation in Women [abstract]. Circulation 2008, 118: 1105.
39. McElduff P, Dobson AJ: How much alcohol and how often? Population based case-control study of alcohol consumption and risk of a major coronary event. BMJ 1997, 314: 1159-1164.
40. Hansagi H, Romelsjö A, Gerhardsson de Verdier M, et al.: Alcohol consumption and stroke mortality. 20-year follow-up of 15, 077 men and women. Stroke 1995, 26: 1768-1773.
41. Ettinger PO, Wu CF, De La Cruz C Jr, et al.: Arrhythmias and the "Holiday Heart": alcohol-associated cardiac rhythm disorders. Am Heart J 1978, 95: 555-562.
42. Mäki T, Toivonen L, Koskinen P, et al.: Effect of ethanol drinking, hangover, and exercise on adrenergic activity and heart rate variability in patients with a history of alcohol-induced atrial fibrillation. Am J Cardiol 1998, 82: 317-322.
43. Djoussé L, Levy D, Benjamin EJ, et al.: Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004, 93: 710-713.
44. Mukamal KJ, Tolstrup JS, Friberg J, et al.: Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 2005, 112: 1736-1742.
45. Frost L, Vestergaard P: Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 2004, 164: 1993-1998.
46. • Conen D, Tedrow UB, Cook NR, et al.: Alcohol consumption and risk of incident atrial fibrillation in women. JAMA 2008, 300: 2489-2496. This is the largest study in women to show that elevated alcohol consumption is related to incident AF.
47. Benjamin EJ, Rice KM, Arking DE, et al.: Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet 2009, 41: 879-881.
48. • Gudbjartsson DF, Arnar DO, Helgadottir A, et al.: Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007, 448: 353-357. This is the first genome-wide association study in patients with AF.
49. Schnabel RB, Sullivan LM, Levy D, et al.: Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009, 373: 739-745.
50. Benjamin EJ, Wolf PA, D'Agostino RB, et al.: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98: 946-952.
51. Friberg J, Scharling H, Gadsbøll N, et al.: Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004, 94: 889-894.
52. Hannon N, Sheehan O, Kelly L, et al.: Stroke associated with atrial fibrillation-incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis 2010, 29: 43-49.
53. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987, 147: 1561-1564.
54. Wolf PA, Mitchell JB, Baker CS, et al.: Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998, 158: 229-234.
55. Wang TJ, Massaro JM, Levy D, et al.: A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003, 290: 1049-1056.
56. Hnatkova K, Waktare JE, Murgatroyd FD, et al.: Age and gender influences on rate and duration of paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 1998, 21: 2455-2458.
57. Rienstra M, van Veldhuisen DJ, Hagens VE, et al.: Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2005, 46: 1298-1306.
58. Ong L, Irvine J, Nolan R, et al.: Gender differences and quality of life in atrial fibrillation: the mediating role of depression. J Psychosom Res 2006, 61: 769-774.
59. Savelieva I, Paquette M, Dorian P, et al.: Quality of life in patients with silent atrial fibrillation. Heart 2001, 85: 216-217.
60. Fuster V, Ryden LE, Cannom DS, et al.: ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114: e257-e354. (Published erratum appears in Circulation 2007, 116: e138.).
61. Gage BF, Waterman AD, Shannon W, et al.: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285: 2864-2870.
62. • Singer DE, Chang Y, Fang MC, et al.: The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009, 151: 297-305. This study examines the risks and benefits of warfarin in patients with AF.
63. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348: 633-638.
64. Benjamin EJ, Chen PS, Bild DE, et al.: Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009, 119: 606-618.
65. • Roy D, Talajic M, Nattel S, et al.: Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358: 2667-2677. This study showed that rate control has a similar outcome as rhythm control in congestive heart failure patients with AF.
66. Wyse DG, Waldo AL, DiMarco JP, et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347: 1825-1833.
67. Lévy S, Camm AJ, Saksena S, et al.: International consensus on nomenclature and classification of atrial fibrillation: A collaborative project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol 2003, 14: 443-445.
68. Gowda RM, Khan IA, Punukollu G, et al.: Female preponderance in ibutilide-induced torsade de pointes. Int J Cardiol 2004, 95: 219-222.
69. Lehmann MH, Hardy S, Archibald D, et al.: Sex difference in risk of torsade de pointes with d, l-sotalol. Circulation 1996, 94: 2535-2541.
70. Gomberg-Maitland M, Wenger NK, Feyzi J, et al.: Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 2006, 27: 1947-1953.
71. Roten L, Rimoldi SF, Schwick N, et al.: Gender differences in patients referred for atrial fibrillation management to a tertiary center. Pacing Clin Electrophysiol 2009, 32: 622-626.
72. Forleo GB, Tondo C, De Luca L, et al.: Gender-related differences in catheter ablation of atrial fibrillation. Europace 2007, 9: 613-620.
73. Khairy P, Nattel S: New insights into the mechanisms and management of atrial fibrillation. CMAJ 2002, 167: 1012-1020.